胚泡
套细胞淋巴瘤
国际预后指标
医学
内科学
比例危险模型
淋巴瘤
细胞周期蛋白D1
增殖指数
Ki-67
胃肠病学
病理
多元分析
肿瘤科
单变量分析
B症状
细胞周期
弥漫性大B细胞淋巴瘤
免疫组织化学
癌症
作者
Riikka Räty,Kaarle Franssila,Heikki Joensuu,Lasse Teerenhovi,Erkki Elonen
标识
DOI:10.1034/j.1600-0609.2002.01677.x
摘要
Mantle cell lymphoma (MCL) is characterised by translocation t(11;14) (q13;q32) leading to rearrangement of bcl1/CCND1 and overexpression of the cell-cycle regulatory protein cyclin D1. We assessed the significance of the cell proliferation rate as an outcome predictor with the five components of the International Prognostic Index (IPI) and the histological subtypes of MCL.The hospital case records and histopathological material of 127 patients diagnosed with MCL in a single centre were reviewed. The cell proliferation rate was assessed by Ki-67 immunostaining and mitosis counting. Cox's multivariate regression model was used in multivariate survival analyses. The median follow-up time was 87 months.The mantle zone/nodular subtype of the common variant (19%) was associated with median survival of 70 months, the diffuse subtype of the common variant (64%) of 35 months, and the blastoid subtype (17%) of 11 months (P < 0.001). Patients with Ki-67 expression in > or = 26% (the upper tertile) of the lymphoma cells had median survival of only 13 months as compared with 45 months in the rest of the patients (P < 0.001). In a multivariate analysis high Ki-67 expression, Ann Arbor stage III-IV, and age over 60 yr had independent influence on survival, whereas serum lactate dehydrogenase level, the number of extranodal disease sites, and performance status did not.The IPI may not be an optimal tool for outcome prediction in MCL, and a better prognostic index may be obtained by including Ki-67 expression and possibly the histological subtype in the index.
科研通智能强力驱动
Strongly Powered by AbleSci AI